Loading...
XNAS
SGMO
Market cap166mUSD
Dec 05, Last price  
0.50USD
1D
-6.45%
1Q
-9.38%
Jan 2017
-83.74%
IPO
-96.69%
Name

Sangamo Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:SGMO chart
P/E
—
P/S
2.89
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.46%
Rev. gr., 5y
-10.81%
Revenues
58m
-67.20%
2,484,0007,885,0009,098,00016,186,00022,187,00020,805,00010,319,00021,655,00024,133,00045,870,00039,539,00019,389,00036,567,00084,452,000102,428,000118,192,000110,701,000111,299,000176,232,00057,800,000
Net income
-98m
L-62.01%
-13,293,000-17,864,000-21,480,000-24,302,000-18,587,000-24,854,000-35,750,000-22,264,000-26,624,000-26,417,000-40,703,000-71,658,000-54,568,000-68,334,000-75,818,000-121,122,000-178,297,000-192,278,000-257,831,000-97,941,000
CFO
-67m
L-70.14%
-4,069,000-14,478,000-16,068,000-17,345,000-6,137,000-23,934,000-25,895,000-8,082,000-19,482,000-5,675,000-33,720,000-65,883,00011,179,00037,152,000-144,402,000169,875,000-233,251,000-223,627,000-224,842,000-67,139,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
URL
https://www.sangamo.com/
IPO date
Apr 06, 2000
Employees
478
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT